DB:PQX1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Biotage's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PQX1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.7%

PQX1

2.6%

DE Life Sciences

0.7%

DE Market


1 Year Return

43.5%

PQX1

53.0%

DE Life Sciences

3.9%

DE Market

Return vs Industry: PQX1 underperformed the German Life Sciences industry which returned 53.1% over the past year.

Return vs Market: PQX1 exceeded the German Market which returned 3.9% over the past year.


Shareholder returns

PQX1IndustryMarket
7 Day3.7%2.6%0.7%
30 Day14.4%10.7%5.3%
90 Day45.3%27.9%17.3%
1 Year43.5%43.5%54.0%53.0%6.2%3.9%
3 Year149.0%142.3%112.7%108.0%1.8%-6.2%
5 Year697.8%622.3%248.8%226.1%9.3%-5.4%

Price Volatility Vs. Market

How volatile is Biotage's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biotage undervalued compared to its fair value and its price relative to the market?

49.23x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PQX1 (€14.54) is trading above our estimate of fair value (€5.25)

Significantly Below Fair Value: PQX1 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PQX1 is good value based on its PE Ratio (49.2x) compared to the XE Life Sciences industry average (65.6x).

PE vs Market: PQX1 is poor value based on its PE Ratio (49.2x) compared to the German market (21x).


Price to Earnings Growth Ratio

PEG Ratio: PQX1 is poor value based on its PEG Ratio (6.3x)


Price to Book Ratio

PB vs Industry: PQX1 is overvalued based on its PB Ratio (10.3x) compared to the XE Life Sciences industry average (6.1x).


Next Steps

Future Growth

How is Biotage forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

7.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PQX1's forecast earnings growth (7.8% per year) is above the savings rate (0.2%).

Earnings vs Market: PQX1's earnings (7.8% per year) are forecast to grow slower than the German market (22.4% per year).

High Growth Earnings: PQX1's earnings are forecast to grow, but not significantly.

Revenue vs Market: PQX1's revenue (10.9% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: PQX1's revenue (10.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PQX1's Return on Equity is forecast to be low in 3 years time (18.5%).


Next Steps

Past Performance

How has Biotage performed over the past 5 years?

21.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PQX1 has high quality earnings.

Growing Profit Margin: PQX1's current net profit margins (17.7%) are lower than last year (17.9%).


Past Earnings Growth Analysis

Earnings Trend: PQX1's earnings have grown significantly by 21.8% per year over the past 5 years.

Accelerating Growth: PQX1's earnings growth over the past year (17.8%) is below its 5-year average (21.8% per year).

Earnings vs Industry: PQX1 earnings growth over the past year (17.8%) exceeded the Life Sciences industry 8.4%.


Return on Equity

High ROE: PQX1's Return on Equity (20.9%) is considered high.


Next Steps

Financial Health

How is Biotage's financial position?


Financial Position Analysis

Short Term Liabilities: PQX1's short term assets (SEK655.1M) exceed its short term liabilities (SEK200.4M).

Long Term Liabilities: PQX1's short term assets (SEK655.1M) exceed its long term liabilities (SEK269.2M).


Debt to Equity History and Analysis

Debt Level: PQX1's debt to equity ratio (11.4%) is considered satisfactory.

Reducing Debt: PQX1's debt to equity ratio has increased from 1% to 11.4% over the past 5 years.

Debt Coverage: PQX1's debt is well covered by operating cash flow (237.4%).

Interest Coverage: PQX1 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Biotage current dividend yield, its reliability and sustainability?

1.34%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PQX1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PQX1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PQX1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PQX1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PQX1 is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PQX1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Tomas Blomquist (50yo)

0.67

Tenure

kr3,853,500

Compensation

Mr. Tomas Blomquist has been CEO and President of Biotage AB since November 6, 2019. Mr. Blomquist served as the Chief Operating Officer of Analyticon Biotechnologies AG. Mr. Blomquist served as Vice Presi ...


CEO Compensation Analysis

Compensation vs Market: Tomas's total compensation ($USD419.66K) is below average for companies of similar size in the German market ($USD1.43M).

Compensation vs Earnings: Insufficient data to compare Tomas's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Tomas Blomquist
CEO & President0.67yrkr3.85m0.023% SEK218.8k
Annette Colin
Chief Financial Officer0.25yrno datano data
Anders Wikström
Executive Vice president of Operations10.17yrsno data0.0048% SEK45.9k
Steve Jordan
Chief Scientific Officerno datano datano data
Lars Bäckman
Chief Legal Officerno datano data0.031% SEK291.6k
Rikke Rytter
Executive Vice President of Global Marketingno datano data0.0029% SEK27.4k
Cecilia Hållner
Global Human Resources Directorno datano data0.00049% SEK4.7k
Jonas Stahlberg
Chief Auditorno datano datano data
Hans Johansson
President of Biosystemsno datano datano data
Scott Carr
Vice President and Chief Executive Officer of North Americano datano datano data

0.7yrs

Average Tenure

53yo

Average Age

Experienced Management: PQX1's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Torben Jörgensen
Chairman0.67yrkr7.13m0.49% SEK4.7m
Peter von Ehrenheim
Director7.25yrskr323.39kno data
Åsa Hedin
Director0.67yrkr47.37kno data
Thomas Eklund
Director14.25yrskr605.57k0.077% SEK729.2k
Mark Bradley
Director1.25yrskr166.15kno data
Love Amcoff
Employee Representative Directorno datano data0.00077% SEK7.3k
Karolina Lawitz
Director8.25yrskr283.39k0.026% SEK247.9k
Annika Gärdlund
Employee Representative Director1.83yrsno datano data
Dan Menasco
Deputy Employee Representative Director0.67yrno datano data
Magnus Mörling
Deputy Employee Representative Director0.67yrno datano data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Board: PQX1's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PQX1 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biotage AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biotage AB
  • Ticker: PQX1
  • Exchange: DB
  • Founded: 1969
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr9.878b
  • Listing Market Cap: kr950.852m
  • Shares outstanding: 65.20m
  • Website: https://www.biotage.com

Number of Employees


Location

  • Biotage AB
  • Box 8
  • Uppsala
  • Uppsala County
  • 751 03
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BITG.FOTCPK (Pink Sheets LLC)YesSeries A Common StockUSUSDJun 2000
BIOTOM (OMX Nordic Exchange Stockholm)YesSeries A Common StockSESEKJun 2000
0GRPLSE (London Stock Exchange)YesSeries A Common StockGBSEKJun 2000
PQX1DB (Deutsche Boerse AG)YesSeries A Common StockDEEURJun 2000
BIOTSBATS-CHIXE (BATS 'Chi-X Europe')YesSeries A Common StockGBSEKJun 2000
PQXXTRA (XETRA Trading Platform)SEK1 SER'A'DEEURFeb 2007

Biography

Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and industrial and large scale products, such as flash purification, metal scavenging, reagents and scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government authorities, and academic institutions; and commercial labs, hospital, CROs, bio-analytical laboratories, food manufacturers, and labs performing for food safety and environmental analysis. It operates in North and South America, Europe, Japan, China, South Korea, India, the Middle East, Africa, and Asia Pacific. The company was founded in 1969 and is headquartered in Uppsala, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/11 21:35
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.